Gher with low andStent Inflation Pressurevery high pressures. Despite statistical adjustment we found a higher restenosis risk following post-dilatation. Post-dilatation was also associated with a lower mortality directly following PCI but the lack of further separation of survival curves over time hints to selection bias. Unmeasured residual confounding factors could partly explain our findings which warrant testing in a prospective, randomized trial.Author ContributionsConceived and designed the experiments: OF GS SKJ NS BL. Analyzed the data: OF GS SKJ BL. Wrote the paper: OF GS SKJ NS BL.
Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell ImmunoglobulinBo Mu1,2*, Huan Zhang1, Xiaoming Cai1, Junbao Yang1, Yuewu Shen1, Baofeng Chen1, Suhua Liang1 The Medical Biology Staff Room of North Sichuan Medical College, Sichuan Nanchong, the People’s Republic of China, 2 Sichuan Key Laboratory of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, North Sichuan Medical College, Nanchong, the People’s Republic of ChinaAbstractAntibody-based immunotherapy has been effectively used for tumor treatment. However, to date, only a few tumorassociated antigens (TAAs) or therapeutic targets have been identified. Identification of more immunogenic antigens is essential for improvements in multiple myeloma (MM) diagnosis and therapy. In this study, we synthesized a polyclonal antibody (PAb) by immunizing rabbits with whole human plasmacytoma ARH-77 cells and identified MM-associated antigens, including enlonase, adipophilin, and HSP90s, among others, via proteomic technologies. 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay showed that 200 mg/mL PAb inhibits the proliferation of ARH-77 cells by over 50 within 48 h. Flow cytometric assay 298690-60-5 indicated that 23977191 PAb treatment significantly increases the number of apoptotic 
cells compared with other treatments (52.1 vs. NS, 7.3 or control rabbit IgG, 9.9 ). In vivo, PAb delayed tumor growth and prolonged the lifespan of mice. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed that PAb also induces statistically significant changes in apoptosis compared with other treatments (P,0.05). We therefore conclude that PAb could be used for the effective screening and identification of TAA. PAb may 23727046 have certain anti-tumor functions in vitro and in vivo. As such, its combination with proteomic technologies could be a promising approach for sieving TAA for the diagnosis and therapy of MM.Citation: Mu B, Zhang H, Cai X, Yang J, Shen Y, et al. (2013) Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin. PLoS ONE 8(4): e59117. doi:10.1371/journal.pone.0059117 Editor: Pranela Rameshwar, University of Medicine and Dentistry of New Jersey, United States of America Received October 25, 2012; Accepted February 11, 2013; Published April 1, 2013 Copyright: ?2013 Mu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This project was supported by National Natural Science Foundation of China, number 81101733 (http://www.nsfc.gov.cn/). The funders had no role in study design, data collection and analysis, Finafloxacin site decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no.Gher with low andStent Inflation Pressurevery high pressures. Despite statistical adjustment we found a higher restenosis risk following post-dilatation. Post-dilatation was also associated with a lower mortality directly following PCI but the lack of further separation of survival curves over time hints to selection bias. Unmeasured residual confounding factors could partly explain our findings which warrant testing in a prospective, randomized trial.Author ContributionsConceived and designed the experiments: OF GS SKJ NS BL. Analyzed the data: OF GS SKJ BL. Wrote the paper: OF GS SKJ NS BL.
Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell ImmunoglobulinBo Mu1,2*, Huan Zhang1, Xiaoming Cai1, Junbao Yang1, Yuewu Shen1, Baofeng Chen1, Suhua Liang1 The Medical Biology Staff Room of North Sichuan Medical College, Sichuan Nanchong, the People’s Republic of China, 2 Sichuan Key Laboratory of Medical Imaging, Affiliated Hospital of North Sichuan Medical College, North Sichuan Medical College, Nanchong, the People’s Republic of ChinaAbstractAntibody-based immunotherapy has been effectively used for tumor treatment. However, to date, only a few tumorassociated antigens (TAAs) or therapeutic targets have been identified. Identification of more immunogenic antigens is essential for improvements in multiple myeloma (MM) diagnosis and therapy. In this study, we synthesized a polyclonal antibody (PAb) by immunizing rabbits with whole human plasmacytoma ARH-77 cells and identified MM-associated antigens, including enlonase, adipophilin, and HSP90s, among others, via proteomic technologies. 3-(4,5-Dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide assay showed that 200 mg/mL PAb inhibits the proliferation of ARH-77 cells by over 50 within 48 h. Flow cytometric assay indicated that 23977191 PAb treatment significantly increases the number of apoptotic cells compared with other treatments (52.1 vs. NS, 7.3 or control rabbit IgG, 9.9 ). In vivo, PAb delayed tumor growth and prolonged the lifespan of mice. Terminal deoxynucleotidyl transferase dUTP nick end labeling assay showed that PAb also induces statistically significant changes in apoptosis compared with other treatments (P,0.05). We therefore conclude that PAb could be used for the effective 
screening and identification of TAA. PAb may 23727046 have certain anti-tumor functions in vitro and in vivo. As such, its combination with proteomic technologies could be a promising approach for sieving TAA for the diagnosis and therapy of MM.Citation: Mu B, Zhang H, Cai X, Yang J, Shen Y, et al. (2013) Screening of Multiple Myeloma by Polyclonal Rabbit Anti-Human Plasmacytoma Cell Immunoglobulin. PLoS ONE 8(4): e59117. doi:10.1371/journal.pone.0059117 Editor: Pranela Rameshwar, University of Medicine and Dentistry of New Jersey, United States of America Received October 25, 2012; Accepted February 11, 2013; Published April 1, 2013 Copyright: ?2013 Mu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Funding: This project was supported by National Natural Science Foundation of China, number 81101733 (http://www.nsfc.gov.cn/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Competing Interests: The authors have declared that no.